Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.35 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.35 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM6B | O15054 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11245204 | 0.87 | LMNA (0.40) | LMNASLC15A2TSHRSLC22A6ALDH1A1 | |
| SCHEMBL1705915 | 0.85 | LMNA (0.44) | LMNATSHRSLC22A6ALDH1A1AKR1B1 | |
| SCHEMBL3154691 | 0.84 | ALDH1A1 (0.41) | LMNASLC15A2ALDH1A1 | |
| SCHEMBL27882078 | 0.84 | TSHR (0.46) | LMNATSHRSLC22A6ALDH1A1AKR1B1 | |
| SCHEMBL5124190 | 0.84 | TSHR (0.46) | LMNATSHRSLC22A6ALDH1A1AKR1B1 | |
| SCHEMBL20708377 | 0.81 | LMNA (0.39) | LMNAKDM4EALDH1A1MAPK1 | |
| SCHEMBL11538765 | 0.80 | SMN1; SMN2 (0.31) | KDM4E | |
| SCHEMBL3474604 | 0.80 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL18402511 | 0.79 | LMNA (0.33) | LMNASLC15A2FFAR3HDAC3HDAC1 | |
| SCHEMBL26061824 | 0.78 | EPHX1 (0.34) | LMNASLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113861014-A | Levulinic acid-13C, preparation method and application | 长沙贝塔医药科技有限公司 | 2021-12-31 | — | — | CN | claimed |
| CN-113861014-B | Levulinic acid (ACA)13C, preparation method and application | 长沙贝塔医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113861014-B | Levulinic acid (ACA)13C, preparation method and application | 长沙贝塔医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113861014-A | Levulinic acid-13C, preparation method and application | 长沙贝塔医药科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| CN-113861014-A | Levulinic acid-13C, preparation method and application | 长沙贝塔医药科技有限公司 | 2021-12-31 | — | — | CN | disclosed |
| US-8088788-B2 | Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2012-01-03 | — | — | US | disclosed |
| US-7968563-B2 | Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-06-28 | — | — | US | disclosed |
| US-7897767-B2 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | NOVARTIS PHARMACEUTICALS CORPORATION | 2010-02-25 | — | — | US | disclosed |
| WO-2007106852-A2 | SUBSTITUTED FUSED[1,2]IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| WO-2006086634-A2 | OXIME AND HYDROXYLAMINE SUBSTITUTED IMIDAZO[4,5-C] RING COMPOUNDS AND METHODS | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1685129-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1505965-B1 | USE OF THE METABOLITE OF VALSARTAN TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2006-08-02 | — | — | EP | disclosed |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | MALININ ALEX (US) | 2005-09-08 | — | — | US | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1505965-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | Novartis AG (CH) | 2005-02-16 | — | — | EP | disclosed |
| WO-2003094915-A1 | USE OF VALSARTAN OT ITS METABOLITE TO INHIBIT PLATELET AGGREGATION | NOVARTIS AG (CH) | 2003-11-20 | — | — | WO | disclosed |
| US-6197774-B1 | THERAPY FOR ASTHMA, SKIN DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-06 | — | — | US | disclosed |
| EP-0244948-A2 | Triazolopyrimidine herbicides | SCHERING AGROCHEMICALS LIMITED (GB) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069427-A9 | Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods | IFNG, IL4, IRF3 | LMNA 2435/4885SLC15A2 3885/4885EGLN1 285/4885 |
| US-20100048654-A1 | USE OF VALSARTAN OR ITS METABOLITE TO IN HIBIT PLATELET AGGREGATION | PDGFRA, PLAT, PTAFR | LMNA 3758/4885SLC15A2 2068/4885EGLN1 453/4885 |
| US-20050197372-A1 | Use of valsartan or its metabolite to inhibit platelet aggregation | PTAFR, PDGFRA, ACE | LMNA 3943/4885SLC15A2 2621/4885EGLN1 1586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.